This policy does not discourage, impede, or prohibit the organization that develops unique biologic materials or intellectual property from commercializing the materials or licensing them for commercial purposes. Investigators may make their materials available to others with appropriate restrictions and licensing terms as they and their institutions deem necessary.
Institutions are reminded that some of these products may be inventions subject to the various laws and regulations applicable to patents and need to be reported. When reporting is required, it should occur at the earliest possible time. (See P.L. 96-517, P.L. 98-620, and 37 CFR 401.)
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Part C: Specific Research Policies and Practices ."
Responsible Science, Volume II: Background Papers and Resource Documents . Washington, DC: The National Academies Press,
Please select a format: